Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Tempest Therapeutics, Inc. announced that the FDA has granted Fast Track Designation to amezalpat (TPST-1120), an oral small molecule designed to treat hepatocellular carcinoma (HCC), recognizing ...

Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to amezalpat, ...

Tempest Therapeutics (NASDAQ:TPST) shares dropped Thursday after the company updated data from an ongoing trial designed to test its PPAR⍺ antagonist, amezalpat (TPST-1120), as a first-line ...

The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective peroxisome proliferator-activated receptor alpha (PPAR-α) antagonist ...

Tempest Therapeutics, Inc. announced that the FDA has granted Orphan Drug Designation to amezalpat (TPST-1120), a selective PPAR⍺ antagonist, for treating hepatocellular carcinoma (HCC), which ...

Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE ...